Tegafur-gimeracil-oteracil Potassium

{
  "id": "MLC-T-ONC-017041",
  "term": "Tegafur-gimeracil-oteracil Potassium",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.",
  "synonyms": [
    "S-1",
    "tegafur, mixture with gimeracil and potassium oxonate",
    "tegafur/gimeracil/oteracil"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tegafur-gimeracil-oteracil-potassium/"
}